Table 1.
Characteristics of all participants.
| Characteristics | Hepatocellular carcinoma | P-value | ||
|---|---|---|---|---|
| Well differentiated (n=16) | Moderately differentiated (n=19) | Poorly differentiated (n=9) | ||
| Gender | 0.975# | |||
| Male | 13 | 15 | 7 | |
| Female | 3 | 4 | 2 | |
| Age (yaer) | 51.4±7.8 | 54.6±9.6 | 55.9±5.8 | 0.371@ |
| Aetiology | 0.581# | |||
| HBV Infection | 14 (87.5) | 15 (79.0) | 6 (66.7) | |
| HCV Infection | 0 (0.0) | 2 (10.5) | 1 (11.1) | |
| Noninfectious | 2 (12.5) | 2 (10.5) | 2 (22.2) | |
| ALT (U/L) | 75.4±97.2 | 63.5±73.0 | 43.1±22.0 | 0.603@ |
| AST (U/L) | 72.1±106.2 | 44.8±27.3 | 37.6±21.1 | 0.371@ |
| Albumin (g/L) | 41.6±5.5 | 40.3±7.7 | 42.4±4.6 | 0.701@ |
| TBil (μmol/L) | 17.8±10.2 | 18.3±12.0 | 14.0±6.3 | 0.580@ |
| PT INR | 1.2±0.1 | 1.1±0.1 | 1.1±0.1 | 0.447@ |
| HBsAg§ | 0.503# | |||
| >250 IU/ml | 10 (71.4) | 13 (86.7) | 4 (66.7) | |
| <250 IU/ml | 4 (28.6) | 2 (13.3) | 2 (33.3) | |
| HBeAg§ | 0.725# | |||
| Positive | 4 (28.6) | 6 (40.0) | 3 (50.0) | |
| Negative | 10 (71.4) | 9 (60.0) | 3 (50.0) | |
| HBV DNA§ | 0.436# | |||
| <3 log IU/ml | 6 (42.9) | 7 (46.6) | 0 (0.0) | |
| 3–6 log IU/ml | 6 (42.9) | 6 (40.0) | 4 (66.6) | |
| >6 log IU/ml | 1 (7.1) | 1 (6.7) | 1 (16.7) | |
| Unkonwn | 1 (7.1) | 1 (6.7) | 1 (16.7) | |
| HCV RNA§ | 0.333# | |||
| <3 log IU/ml | 0 | 2 (100.0) | 0 (0.0) | |
| >3 log IU/ml | 0 | 0 (0.0) | 1 (100.0) | |
| Nodule size (cm) | 4.4±2.4 | 3.8±1.7 | 7.1±3.8* | 0.009@ |
| Number of Nodules | 0.581# | |||
| 1 | 14 (87.5) | 13 (68.4) | 8 (88.9) | |
| 2 | 2 (12.5) | 3 (15.8) | 1 (11.1) | |
| 3 | 0 (0.0) | 3 (15.8) | 0 (0.0) | |
| Lymphatic metastasis | 0.075# | |||
| Positve | 3 (18.7) | 0 (0.0) | 2 (22.2) | |
| Negative | 13 (81.3) | 19 (100.0) | 7 (77.8) | |
| Portal invasion | 0.092# | |||
| Positive | 1 (6.2) | 0 (0.0) | 2 (22.2) | |
| Negative | 15 (93.8) | 19 (100.0) | 7 (77.8) | |
| BCLC stage | 0.007# | |||
| Early | 11 (68.8) | 13 (68.4) | 5 (55.6) | |
| Intermediate | 1 (6.2) | 6 (31.6) | 0 (0.0) | |
| Advanced | 4 (25.0) | 0 (0.0) | 4 (44.4) | |
Data are described as mean ± standard deviation or number (%).
@
One-way analysis of variance (ANOVA);
#
Fisher’s exact test;
§
data are not available for all patients.
*
P-values are for comparisons between patients with and without poorly-differentiated HCC tissue.
AKR1B10 – aldo-keto reductase family 1 member B10; AFP – alpha-fetoprotein; ALT – alanine aminotransferase; AST – aspartate aminotransferase; TBil – total bilirubin; PT INR – prothrombin time international normalized ratio; HBsAg – hepatitis B surface antigen; HBeAg – hepatitis e antigen; BCLC – Barcelona Clinic Liver Cancer.